Search

Your search keyword '"Sanders‐van Wijk, Sandra"' showing total 171 results
Start Over Author "Sanders‐van Wijk, Sandra"
171 results on '"Sanders‐van Wijk, Sandra"'

3. High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life

Author

Ramonfaur, Diego, primary, Buckley, Leo F., additional, Arthur, Victoria, additional, Yang, Yimin, additional, Claggett, Brian L., additional, Ndumele, Chiadi E., additional, Walker, Keenan A., additional, Austin, Thomas, additional, Odden, Michelle C., additional, Floyd, James S., additional, Sanders-van Wijk, Sandra, additional, Njoroge, Joyce, additional, Kizer, Jorge R., additional, Kitzman, Dalane, additional, Konety, Suma H., additional, Schrack, Jennifer, additional, Liu, Fangyu, additional, Windham, B. Gwen, additional, Palta, Priya, additional, Coresh, Josef, additional, Yu, Bing, additional, and Shah, Amil M., additional

Published
2024
Full Text
View/download PDF

5. Absence of an increased wall thickness does not rule out cardiac amyloidosis.

Author

Muller, Steven A., Achten, Anouk, van der Meer, Manon G., Zwetsloot, Peter-Paul, Sanders-van Wijk, Sandra, van der Harst, Pim, van Tintelen, J. Peter, te Riele, Anneline S. J. M., van Empel, Vanessa, Knackstedt, Christian, and Oerlemans, Marish I. F. J.

Subjects
SINGLE-photon emission computed tomography, CARDIAC magnetic resonance imaging, RADIONUCLIDE imaging, VENTRICULAR septum, CARDIAC amyloidosis, VENTRICULAR ejection fraction, HEART failure
Abstract

This document is a letter to the editor of the journal Amyloid. The authors discuss the diagnosis of transthyretin amyloid (ATTR) cardiomyopathy (ATTR-CM), a progressive and life-threatening heart condition. They question the current diagnostic criteria, which suggest that a wall thickness of ≥12 mm should be used to screen for cardiac amyloidosis. The authors conducted a study to determine the correlation between wall thickness measurements and tracer uptake in bone scintigraphy, as well as the prevalence of a wall thickness <12 mm in ATTR-CM patients. They found that a significant number of patients with ATTR-CM did not have an increased wall thickness, suggesting that a wall thickness <12 mm does not rule out cardiac amyloidosis. The authors recommend further research to determine if these patients benefit from treatment. [Extracted from the article]

Published
2024
Full Text
View/download PDF

7. Webtool to enhance the accuracy of diagnostic algorithms for HFpEF: a prospective cross‐over study

Author

Weerts, Jerremy, primary, Amin, Hesam, additional, Barandiarán Aizpurua, Arantxa, additional, Gevaert, Andreas B., additional, Handoko, M. Louis, additional, Dauw, Jeroen, additional, Tun, Han Naung, additional, Rommel, Karl‐Philipp, additional, Verbrugge, Frederik H., additional, Kresoja, Karl‐Patrik, additional, Sanders‐van Wijk, Sandra, additional, Brunner‐La Rocca, Hans‐Peter, additional, Bayés‐Genís, Antoni, additional, Lumens, Joost, additional, Knackstedt, Christian, additional, and van Empel, Vanessa P.M., additional

Published
2023
Full Text
View/download PDF

8. Influence of Individual Personality Traits of the Reader on Visual Assessment of Left Ventricular Ejection Fraction: Another Reason to Abandon Visual Assessment

Author

Knackstedt, Christian, primary, Ramaekers, Bram, additional, Schummers, Georg, additional, Schreckenberg, Marcus, additional, Faessen, Jelle, additional, Marx, Nikolaus, additional, Becker, Michael, additional, Sanders-van Wijk, Sandra, additional, van Empel, Vanessa, additional, Norra, Christine, additional, Kunert, Hanns Jürgen, additional, Brunner-La Rocca, Hans-Peter, additional, Altiok, E., additional, Becker, M., additional, Bekkers, S.C.A.M., additional, Barandiaran, A., additional, Brandenburg, V.M., additional, Brunner-la Rocca, H.P., additional, Cheriex, E.C., additional, Dettori, R., additional, Dinh, N.H.T., additional, Driessen, R., additional, van Empel, V., additional, Ertmer, J., additional, Eurlings, C., additional, Geyik, Z., additional, Hamada, S., additional, Heymans, S.R.B., additional, Holvoet, W., additional, Ilhan, M., additional, Jaarsma, C., additional, Janssen, R., additional, Kästner, W., additional, Kersten, A., additional, Lencer, N.H.K.M., additional, Luermans, J., additional, Mischke, K., additional, Pisters, R., additional, Poels, E., additional, Pluimen, M., additional, Schalla, S.M., additional, Scheenstra, B., additional, Sanders- van Wijk, S., additional, Schöder, J.W., additional, Skobel, E., additional, Stipdonk, T., additional, Stöhr, R., additional, Streukens, S.A.F., additional, Strik, M., additional, Tchaikovsky, V., additional, Theunissen, R.A.L.J., additional, Ubachs, J., additional, Vainer, J., additional, Vernooy, K., additional, Weijs, B., additional, Winkler, P., additional, and van Workum, S., additional

Published
2023
Full Text
View/download PDF

11. Influence of Individual Personality Traits of the Reader on Visual Assessment of Left Ventricular Ejection Fraction: Another Reason to Abandon Visual Assessment

Author

Altiok, E., Becker, M., Bekkers, S.C.A.M., Barandiaran, A., Brandenburg, V.M., Brunner-la Rocca, H.P., Cheriex, E.C., Dettori, R., Dinh, N.H.T., Driessen, R., van Empel, V., Ertmer, J., Eurlings, C., Geyik, Z., Hamada, S., Heymans, S.R.B., Holvoet, W., Ilhan, M., Jaarsma, C., Janssen, R., Kästner, W., Kersten, A., Lencer, N.H.K.M., Luermans, J., Mischke, K., Pisters, R., Poels, E., Pluimen, M., Schalla, S.M., Scheenstra, B., Sanders-van Wijk, S., Schöder, J.W., Skobel, E., Stipdonk, T., Stöhr, R., Streukens, S.A.F., Strik, M., Tchaikovsky, V., Theunissen, R.A.L.J., Ubachs, J., Vainer, J., Vernooy, K., Weijs, B., Winkler, P., van Workum, S., Knackstedt, Christian, Ramaekers, Bram, Schummers, Georg, Schreckenberg, Marcus, Faessen, Jelle, Marx, Nikolaus, Becker, Michael, Sanders-van Wijk, Sandra, van Empel, Vanessa, Norra, Christine, Kunert, Hanns Jürgen, and Brunner-La Rocca, Hans-Peter

Published
2023
Full Text
View/download PDF

12. Novel concept to guide systolic heart failure medication by repeated biomarker testing—results from TIME-CHF in context of predictive, preventive, and personalized medicine

Author

Davarzani, Nasser, Sanders-van Wijk, Sandra, Maeder, Micha T., Rickenbacher, Peter, Smirnov, Evgueni, Karel, Joël, Suter, Thomas, de Boer, Rudolf A., Block, Dirk, Rolny, Vinzent, Zaugg, Christian, Pfisterer, Matthias E., Peeters, Ralf, Brunner-La Rocca, Hans-Peter, and for the TIME-CHF investigators

Published
2018
Full Text
View/download PDF

18. Use of artificial intelligence to assess the risk of coronary artery disease without additional (non-invasive) testing: validation in a low-risk to intermediate-risk outpatient clinic cohort

Author

Eurlings, Casper G M J, primary, Bektas, Sema, additional, Sanders-van Wijk, Sandra, additional, Tsirkin, Andrew, additional, Vasilchenko, Vasily, additional, Meex, Steven J R, additional, Failer, Michael, additional, Oehri, Caroline, additional, Ruff, Peter, additional, Zellweger, Michael J, additional, and Brunner-La Rocca, Hans-Peter, additional

Published
2022
Full Text
View/download PDF

19. Fluid REStriction in Heart Failure vs Liberal Fluid UPtake: Rationale and Design of the Randomized FRESH-UP Study

Author

Cardiologie Arts-onderzoekers, Herrmann, Job J, Beckers-Wesche, Fabienne, Baltussen, Lisette E H J M, Verdijk, Marjolein H I, Bellersen, Louise, Brunner-la Rocca, Hans-Peter, Jaarsma, Tiny, Pisters, Ron, Sanders-van Wijk, Sandra, Rodwell, Laura, Van Royen, Niels, Gommans, D H Frank, Van Kimmenade, Roland R J, Cardiologie Arts-onderzoekers, Herrmann, Job J, Beckers-Wesche, Fabienne, Baltussen, Lisette E H J M, Verdijk, Marjolein H I, Bellersen, Louise, Brunner-la Rocca, Hans-Peter, Jaarsma, Tiny, Pisters, Ron, Sanders-van Wijk, Sandra, Rodwell, Laura, Van Royen, Niels, Gommans, D H Frank, and Van Kimmenade, Roland R J

Published
2022

20. Improving diagnosis and risk stratification across the ejection fraction spectrum: the Maastricht Cardiomyopathy registry

Author

Henkens, Michiel T.H.M., primary, Weerts, Jerremy, additional, Verdonschot, Job A.J., additional, Raafs, Anne G., additional, Stroeks, Sophia, additional, Sikking, Maurits A., additional, Amin, Hesam, additional, Mourmans, Sanne G.J., additional, Geraeds, Chrit B.G., additional, Sanders‐van Wijk, Sandra, additional, Barandiarán Aizpurua, Arantxa, additional, Uszko‐Lencer, Nicole H.M.K., additional, Krapels, Ingrid P.C., additional, Wolffs, Petra F.G., additional, Brunner, Han G., additional, Leeuwen, Rick E.W., additional, Verhesen, Wouter, additional, Schalla, Simon M., additional, Stipdonk, Antonius W.M., additional, Knackstedt, Christian, additional, Li, Xiaofei, additional, Abdul Hamid, Myrurgia A., additional, Paassen, Pieter, additional, Hazebroek, Mark R., additional, Vernooy, Kevin, additional, Brunner‐La Rocca, Hans‐Peter, additional, Empel, Vanessa P.M., additional, and Heymans, Stephane R.B., additional

Published
2022
Full Text
View/download PDF

21. The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction

Author

Sanders-van Wijk, Sandra, Barandiaran Aizpurua, Arantxa, Brunner-La Rocca, Hans-Peter, Henkens, Michiel THM, Weerts, Jerremy, Knackstedt, Christian, Uszko-Lencer, Nicole, Heymans, Stephane, van Empel, Vanessa, RS: Carim - H01 Clinical atrial fibrillation, Cardiologie, MUMC+: MA Med Staf Artsass Cardiologie (9), RS: Carim - H02 Cardiomyopathy, and MUMC+: MA Med Staf Spec Cardiologie (9)

Subjects
Science & Technology, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, Life Sciences & Biomedicine
Abstract

ispartof: EUROPEAN JOURNAL OF HEART FAILURE vol:23 issue:5 pages:838-840 ispartof: location:England status: published

Published
2021

22. The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction

Author

Weerts, Jerremy, primary, Barandiarán Aizpurua, Arantxa, additional, Henkens, Michiel T H M, additional, Lyon, Aurore, additional, van Mourik, Manouk J W, additional, van Gemert, Mathijs R A A, additional, Raafs, Anne, additional, Sanders-van Wijk, Sandra, additional, Bayés-Genís, Antoni, additional, Heymans, Stephane R B, additional, Crijns, Harry J G M, additional, Brunner-La Rocca, Hans-Peter, additional, Lumens, Joost, additional, van Empel, Vanessa P M, additional, and Knackstedt, Christian, additional

Published
2021
Full Text
View/download PDF

24. Re-appraisal of the obesity paradox in heart failure : a meta-analysis of individual data

Author

Marcks, Nick, Aimo, Alberto, Januzzi, James L., Jr., Vergaro, Giuseppe, Clerico, Aldo, Latini, Roberto, Meessen, Jennifer, Anand, Inder S., Cohn, Jay N., Gravning, Jorgen, Ueland, Thor, Bayes-Genis, Antoni, Lupon, Josep, de Boer, Rudolf A., Yoshihisa, Akiomi, Takeishi, Yasuchika, Egstrup, Michael, Gustafsson, Ida, Gaggin, Hanna K., Eggers, Kai M., Huber, Kurt, Tentzeris, Ioannis, Ripoli, Andrea, Passino, Claudio, Sanders-van Wijk, Sandra, Emdin, Michele, Brunner-La Rocca, Hans-Peter, Marcks, Nick, Aimo, Alberto, Januzzi, James L., Jr., Vergaro, Giuseppe, Clerico, Aldo, Latini, Roberto, Meessen, Jennifer, Anand, Inder S., Cohn, Jay N., Gravning, Jorgen, Ueland, Thor, Bayes-Genis, Antoni, Lupon, Josep, de Boer, Rudolf A., Yoshihisa, Akiomi, Takeishi, Yasuchika, Egstrup, Michael, Gustafsson, Ida, Gaggin, Hanna K., Eggers, Kai M., Huber, Kurt, Tentzeris, Ioannis, Ripoli, Andrea, Passino, Claudio, Sanders-van Wijk, Sandra, Emdin, Michele, and Brunner-La Rocca, Hans-Peter

Abstract

Background Higher body mass index (BMI) is associated with better outcome compared with normal weight in patients with HF and other chronic diseases. It remains uncertain whether the apparent protective role of obesity relates to the absence of comorbidities. Therefore, we investigated the effect of BMI on outcome in younger patients without co-morbidities as compared to older patients with co-morbidities in a large heart failure (HF) population. Methods In an individual patient data analysis from pooled cohorts, 5,819 patients with chronic HF and data available on BMI, co-morbidities and outcome were analysed. Patients were divided into four groups based on BMI (i.e. <= 18.5 kg/m(2), 18.5-25.0 kg/m(2); 25.0-30.0 kg/m(2); 30.0 kg/m(2)). Primary endpoints included all-cause mortality and HF hospitalization-free survival. Results Mean age was 65 +/- 12 years, with a majority of males (78%), ischaemic HF and HF with reduced ejection fraction. Frequency of all-cause mortality or HF hospitalization was significantly worse in the lowest two BMI groups as compared to the other two groups; however, this effect was only seen in patients older than 75 years or having at least one relevant co-morbidity, and not in younger patients with HF only. After including medications and N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin concentrations into the model, the prognostic impact of BMI was largely absent even in the elderly group with co-morbidity. Conclusions The present study suggests that obesity is a marker of less advanced disease, but does not have an independent protective effect in patients with chronic HF. [GRAPHICS] .

Published
2021
Full Text
View/download PDF

26. Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data

Author

Marcks, Nick, primary, Aimo, Alberto, additional, Januzzi, James L., additional, Vergaro, Giuseppe, additional, Clerico, Aldo, additional, Latini, Roberto, additional, Meessen, Jennifer, additional, Anand, Inder S., additional, Cohn, Jay N., additional, Gravning, Jørgen, additional, Ueland, Thor, additional, Bayes-Genis, Antoni, additional, Lupón, Josep, additional, de Boer, Rudolf A., additional, Yoshihisa, Akiomi, additional, Takeishi, Yasuchika, additional, Egstrup, Michael, additional, Gustafsson, Ida, additional, Gaggin, Hanna K., additional, Eggers, Kai M., additional, Huber, Kurt, additional, Tentzeris, Ioannis, additional, Ripoli, Andrea, additional, Passino, Claudio, additional, Sanders-van Wijk, Sandra, additional, Emdin, Michele, additional, and Brunner-La Rocca, Hans-Peter, additional

Published
2021
Full Text
View/download PDF

28. The HFA‐PEFF andH 2 FPEFscores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction

Author

Sanders‐van Wijk, Sandra, primary, Barandiarán Aizpurua, Arantxa, additional, Brunner‐La Rocca, Hans‐Peter, additional, Henkens, Michiel T.H.M., additional, Weerts, Jerremy, additional, Knackstedt, Christian, additional, Uszko‐Lencer, Nicole, additional, Heymans, Stephane, additional, and van Empel, Vanessa, additional

Published
2020
Full Text
View/download PDF

32. Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction. A systematic review

Author

Henkens, Michiel T.H.M., primary, Remmelzwaal, Sharon, additional, Robinson, Emma L., additional, Ballegooijen, Adriana J., additional, Barandiarán Aizpurua, Arantxa, additional, Verdonschot, Job A.J., additional, Raafs, Anne G., additional, Weerts, Jerremy, additional, Hazebroek, Mark R., additional, Sanders‐van Wijk, Sandra, additional, Handoko, M. Louis, additional, Ruijter, Hester M., additional, Lam, Carolyn S.P., additional, Boer, Rudolf A., additional, Paulus, Walter J., additional, Empel, Vanessa P.M., additional, Vos, Rein, additional, Brunner‐La Rocca, Hans‐Peter, additional, Beulens, Joline W.J., additional, and Heymans, Stephane R.B., additional

Published
2020
Full Text
View/download PDF

33. Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME‐CHF trial

Author

Stöhr, Robert, primary, Brandenburg, Vincent M., additional, Heine, Gunnar H., additional, Maeder, Micha T., additional, Leibundgut, Gregor, additional, Schuh, Alexander, additional, Jeker, Urs, additional, Pfisterer, Matthias, additional, Sanders‐van Wijk, Sandra, additional, and Brunner‐la Rocca, Hans‐Peter, additional

Published
2020
Full Text
View/download PDF

35. Validation of the HFA-PEFF score for the diagnosis of heart failure with preserved ejection fraction.

Author

Barandiarán Aizpurua, Arantxa, Sanders‐van Wijk, Sandra, Brunner‐La Rocca, Hans‐Peter, Henkens, Michiel, Heymans, Stephane, Beussink‐Nelson, Lauren, Shah, Sanjiv J., Empel, Vanessa P.M., Sanders-van Wijk, Sandra, Brunner-La Rocca, Hans-Peter, Beussink-Nelson, Lauren, and van Empel, Vanessa P M

Subjects
*RECEIVER operating characteristic curves, *NATRIURETIC peptides, *ECHOCARDIOGRAPHY, *RESEARCH, *RESEARCH methodology, *MEDICAL cooperation, *EVALUATION research, *COMPARATIVE studies, *RESEARCH funding, *STROKE volume (Cardiac output), *HEART failure, *LONGITUDINAL method
Abstract

Aims: Diagnosing heart failure with preserved ejection fraction (HFpEF) is challenging. The newly proposed HFA-PEFF algorithm entails a stepwise approach. Step 1, typically performed in the ambulatory setting, establishes a pre-test likelihood. The second step calculates a score based on echocardiography and natriuretic peptides. The aim of this study is to validate the diagnostic value and establish the clinical impact of the second step of the HFA-PEFF score.Methods and Results: The second step of the HFA-PEFF score was evaluated in two independent, prospective cohorts, i.e. the Maastricht cohort (228 HFpEF patients and 42 controls) and the Northwestern Chicago cohort (459 HFpEF patients). In Maastricht, the HFA-PEFF score categorizes 11 (4%) of the total cohort with suspected HFpEF in the low-likelihood (0-1 points) and 161 (60%) in the high-likelihood category (5-6 points). A high HFA-PEFF score can rule in HFpEF with high specificity (93%) and positive predictive value (98%). A low score can rule out HFpEF with a sensitivity of 99% and a negative predictive value of 73%. The diagnostic accuracy of the score is 0.90 (0.84-0.96), by the area under the curve of the receiver operating characteristic curve. However, 98 (36%) are classified in the intermediate-likelihood category, where additional testing is advised. The distribution of the score shows a similar pattern in the Northwestern (Chicago) and Maastricht HFpEF patients (53% vs. 65% high, 43% vs. 34% intermediate, 4.8% vs. 1.3% low).Conclusion: This study validates and characterizes the HFA-PEFF score in two independent, well phenotyped cohorts. We demonstrate that the HFA-PEFF score is helpful in clinical practice for the diagnosis of HFpEF. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

36. Guiding Heart Failure Therapy After GUIDE-IT Back to the Drawing Board

Author

Brunner-La Rocca, Hans-Peter, Sanders-van Wijk, Sandra, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: CARIM - R2.02 - Cardiomyopathy

Subjects
left ventricular dysfunction, NATRIURETIC PEPTIDE, MORTALITY, biomarkers, heart failure, economics, TIME-CHF, COST-EFFECTIVENESS, quality of life, HOSPITALIZATION, MANAGEMENT, TRIAL, ELDERLY-PATIENTS, STANDARD MEDICAL THERAPY
Published
2018

39. The HFA‐PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction.

Author

Sanders‐van Wijk, Sandra, Barandiarán Aizpurua, Arantxa, Brunner‐La Rocca, Hans‐Peter, Henkens, Michiel T.H.M., Weerts, Jerremy, Knackstedt, Christian, Uszko‐Lencer, Nicole, Heymans, Stephane, and van Empel, Vanessa

Subjects
*HEART failure patients, *HEART failure, *LEFT ventricular hypertrophy
Abstract

Patients with an assigned H SB 2 sb FPEF category higher than their assigned HFA-PEFF category (H SB 2 sb FPEF > HFA-PEFF) most often suffered from AF (82.0% vs. 14.0% and 61%, I P i < 0.001) and had the highest BMI (33.5 ± 6.5 vs. 27.9 ± 4.9 and 31.0 ± 6.1, I P i < 0.001). The HFA-PEFF and H2FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction The H SB 2 sb FPEF and HFA-PEFF scores have recently been proposed to solve the clinical dilemma of diagnosing heart failure with preserved ejection fraction (HFpEF).1,2 The H SB 2 sb FPEF score includes four clinical [age, body mass index (BMI), atrial fibrillation (AF) and hypertension] and two echocardiographic items (E/e' and right ventricular pressure). [Extracted from the article]

Published
2021
Full Text
View/download PDF

40. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF.

Author

Davarzani, Nasser, Sanders–van Wijk, Sandra, Karel, Joël, Maeder, Micha T., Leibundgut, Gregor, Gutmann, Marc, Pfisterer, Matthias E., Rickenbacher, Peter, Peeters, Ralf, Brunner–la Rocca, Hans-Peter, Sanders-van Wijk, Sandra, and Brunner-la Rocca, Hans-Peter

Abstract

Background: Although heart failure (HF) patients are known to experience repeated hospitalizations, most studies evaluated only time to first event. N-Terminal B-type natriuretic peptide (NT-proBNP)-guided therapy has not convincingly been shown to improve HF-specific outcomes, and effects on recurrent all-cause hospitalization are uncertain. Therefore, we investigated the effect of NT-proBNP-guided therapy on recurrent events in HF with the use of a time-between-events approach in a hypothesis-generating analysis.Methods and Results: The Trial of Intensified Versus Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized 499 HF patients, aged ≥60 years, left ventricular ejection fraction ≤45%, New York Heart Association functional class ≥I,I to NT-proBNP-guided versus symptom-guided therapy for 18 months, with further follow-up for 5.5 years. The effect of NT-proBNP-guided therapy on recurrent HF-related and all-cause hospitalizations and/or all-cause death was explored. One hundred four patients (49 NT-proBNP-guided, 55 symptom-guided) experienced 1 and 275 patients (133 NT-proBNP-guided, 142 symptom-guided) experienced ≥2 all-cause hospitalization events. Regarding HF hospitalization, 132 patients (57 NT-proBNP-guided, 75 symptom-guided) experienced 1 and 122 patients (57 NT-proBNP-guided, 65 symptom-guided) experienced ≥2 events. NT-proBNP-guided therapy was significant in preventing 2nd all-cause hospitalizations (hazard ratio [HR] 0.83; P = .01), in contrast to nonsignificant results in preventing 1st all-cause hospitalization events (HR 0.91; P = .35). This was not the case regarding HF hospitalization events (HR 0.85 [P = .14] vs HR 0.73 [P = .01]) The beneficial effect of NT-proBNP-guided therapy was seen only in patients aged <75 years, and not in those aged ≥75 years (interaction terms with P = .01 and P = .03 for all-cause hospitalization and HF hospitalization events, respectively).Conclusion: NT-proBNP-guided therapy reduces the risk of recurrent events in patients <75 years of age. This included all-cause hospitalization by mainly reducing later events, adding knowledge to the neutral effect on this end point when shown using time-to-first-event analysis only.Clinical Trial Registration: isrctn.org, identifier: ISRCTN43596477. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

41. Improving kNowledge Transfer to Efficaciously RAise the level of Contemporary Treatment in Heart Failure (INTERACT-in-HF): Study protocol of a mixed methods study

Author

Baldewijns, Karolien, primary, Bektas, Sema, additional, Boyne, Josiane, additional, Rohde, Carla, additional, De Maesschalck, Lieven, additional, De Bleser, Leentje, additional, Brandenburg, Vincent, additional, Knackstedt, Christian, additional, Devillé, Aleidis, additional, Sanders-Van Wijk, Sandra, additional, and Brunner La Rocca, Hans-Peter, additional

Published
2017
Full Text
View/download PDF

42. Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure)

Author

Sanders-van Wijk, Sandra, van Asselt, Antoinette D I, Rickli, Hans, Estlinbaum, Werner, Erne, Paul, Rickenbacher, Peter, Vuillomenet, Andre, Peter, Martin, Pfisterer, Matthias E, and Brunner-La Rocca, Hans-Peter

Subjects
amino terminal pro brain natriuretic peptide, heart failure, Cost effectiveness, male, quality adjusted life year, ISRCTN43596477, human, randomized controlled trial (topic), intermethod comparison, health care economics and organizations, cost control, adult, clinical effectiveness, cost effectiveness analysis, elderly care, drug effect, article, health care cost, major clinical study, aged, comorbidity, female, priority journal, NT-proBNP, multicenter study (topic), treatment outcome, heart left ventricle ejection fraction
Abstract

OBJECTIVES: This study aimed to assess cost-effectiveness of N-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided versus symptom-guided therapy in heart failure (HF) patients ≥60 years old. BACKGROUND: Cost-effectiveness of NT-proBNP guidance in HF patients is unclear. It may create additional costs with uncertain benefits. METHODS: In the TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure), patients with left ventricular ejection fraction (LVEF) of ≤45% were randomized to receive intensified NT-proBNP-guided therapy or standard, symptom-guided therapy. For cost-effectiveness analysis, 467 (94%) patients (age 76 ± 7 years, 66% male) were eligible. Incremental cost-effectiveness was calculated as incremental costs per gained life-year and quality-adjusted life-year (QALY) within the 18-month trial period, as defined per protocol. RESULTS: NT-proBNP-guided therapy was dominant (i.e., more effective and less costly) over symptom-guided therapy, saving $2,979 USD (2.5 to 97.5% confidence interval [CI]: $8,758 to $3,265) per patient, with incremental effectiveness of +0.07 life-years and +0.05 QALYs. The probability of NT-proBNP-guided therapy being dominant was 80%, and the probability of saving 1 life-year or QALY at a cost of $50,000 was 97% and 93%, respectively. Exclusion of residence costs resulted in an incremental cost-effectiveness ratio (ICER) of $5,870 per life-year gained. Cost-effectiveness of NT-proBNP-guided therapy was most pronounced in patients

Published
2013

43. Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening

Author

Van Aelst, Lucas N.L., primary, Voss, Sandra, additional, Carai, Paolo, additional, Van Leeuwen, Rick, additional, Vanhoutte, Davy, additional, Sanders-van Wijk, Sandra, additional, Eurlings, Luc, additional, Swinnen, Melissa, additional, Verheyen, Fons K., additional, Verbeken, Eric, additional, Nef, Holger, additional, Troidl, Christian, additional, Cook, Stuart A., additional, Brunner-La Rocca, Hans-Peter, additional, Möllmann, Helge, additional, Papageorgiou, Anna-Pia, additional, and Heymans, Stephane, additional

Published
2015
Full Text
View/download PDF

44. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF

Author

Sanders-van Wijk, Sandra, Maeder, Micha T, Nietlispach, Fabian, Rickli, Hans, Estlinbaum, Werner, Erne, Paul, Rickenbacher, Peter, Peter, Martin, Pfisterer, Matthias P, Brunner-La Rocca, Hans-Peter, Sanders-van Wijk, Sandra, Maeder, Micha T, Nietlispach, Fabian, Rickli, Hans, Estlinbaum, Werner, Erne, Paul, Rickenbacher, Peter, Peter, Martin, Pfisterer, Matthias P, and Brunner-La Rocca, Hans-Peter

Abstract

BACKGROUND Therapy guided by N-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels may improve outcomes in patients with chronic heart failure (HF), especially in younger patients with reduced left ventricular ejection fraction. It remains unclear whether treatment effects persist after discontinuation of the NT-proBNP-guided treatment strategy. METHODS AND RESULTS Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure randomized 499 patients with HF aged≥60 years with left ventricular ejection fraction≤45% to intensified, NT-proBNP-guided versus standard, symptom-guided therapy into prespecified age groups (60-74 and ≥75 years) during 18 months. A total of 329 patients (92%) alive at 18 months agreed to long-term follow-up. HF medication was intensified to a larger extent in the NT-proBNP-guided group. During long-term, NT-proBNP-guided therapy did not improve hospital-free (primary end point: hazard ratio, 0.87; 95% confidence interval, 0.71-1.06; P=0.16) or overall survival (hazard ratio, 0.85; 95% confidence interval, 0.64-1.13; P=0.25) but did improve HF hospitalization-free survival (hazard ratio, 0.70; 95% confidence interval, 0.55-0.90; P=0.005). Patients aged 60 to 74 years had benefit from NT-proBNP-guided therapy on the primary end point and HF hospitalization-free survival, whereas patients aged≥75 years did not (P<0.10 for interaction). In landmark analysis, there was no regression to the mean after cessation of the NT-proBNP-guided strategy. More intensified HF medication at month 12 was associated with better long-term HF hospitalization-free and overall survival. CONCLUSIONS Intensified, NT-proBNP-guided therapy did not improve the primary end point compared with symptom-guided therapy but did improve HF hospitalization-free survival. Within the subgroup of patients aged 60 to 74 years, it improved clinical outcome including the primary end point. These effects did not disappear after cessation o

Published
2014

46. Long-Term Results of Intensified, N-Terminal-Pro-B-Type Natriuretic Peptide–Guided Versus Symptom-Guided Treatment in Elderly Patients With Heart Failure

Author

Sanders-van Wijk, Sandra, primary, Maeder, Micha T., additional, Nietlispach, Fabian, additional, Rickli, Hans, additional, Estlinbaum, Werner, additional, Erne, Paul, additional, Rickenbacher, Peter, additional, Peter, Martin, additional, Pfisterer, Matthias P., additional, and Brunner-La Rocca, Hans-Peter, additional

Published
2014
Full Text
View/download PDF

49. Multimarker Strategy for Short-Term Risk Assessment in Patients With Dyspnea in the Emergency Department The MARKED (Multi mARKer Emergency Dyspnea)-Risk Score

Author

Eurlings, Luc W., Sanders-van Wijk, Sandra, van Kimmenade, Roland, Osinski, Aart, van Helmond, Lidwien, Vallinga, Maud, Crijns, Harry J., van Dieijen-Visser, Marja P., Brunner-La Rocca, Hans-Peter, Pinto, Yigal M., Amsterdam Cardiovascular Sciences, and Cardiology

Subjects
high-sensitivity cardiac troponin T, N-terminal pro-BNP, biomarkers, Galectin-3, heart failure, high-sensitivity C-reactive protein, prognosis, dyspnea, Cystatin-C
Abstract

Objectives The study aim was to determine the prognostic value of a multimarker strategy for risk-assessment in patients presenting to the emergency department (ED) with dyspnea. Background Combining biomarkers with different pathophysiological backgrounds may improve risk stratification in dyspneic patients in the ED. Methods The study prospectively investigated the prognostic value of the biomarkers N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), Cystatin-C (Cys-C), high-sensitivity C-reactive protein (hs-CRP), and Galectin-3 (Gal-3) for 90-day mortality in 603 patients presenting to the ED with dyspnea as primary complaint. Results hs-CRP, hs-cTnT, Cyst-C, and NT-proBNP were independent predictors of 90-day mortality. The number of elevated biomarkers was highly associated with outcome (odds ratio: 2.94 per biomarker, 95% confidence interval [CI]: 2.29 to 3.78, p = 75 years, systolic blood pressure = 0.04 mu g/l, hs-CRP >= 25 mg/l, and Cys-C >= 1.125 mg/l had excellent prognostic performance (area under the curve: 0.85, 95% CI: 0.81 to 0.89), was robust in internal validation analyses and could identify patients with very low ( = 3

Full Text
View/download PDF

50. The relationship between the use of loop diuretics, congestion and heart failure outcome

Author

Simonavicius, Justas, Brunner-La Rocca, Hanspeter, Knackstedt, Christian, Sanders - van Wijk, Sandra, Cardiologie, and RS: Carim - Heart

Subjects
Congestion, Heart failure, Diuretics, Biomarkers
Abstract

Despite advances in management, the long-term prognosis of heart failure patients remains poor. Fluid accumulation in the human body is called congestion, and the phenomenon is known to attribute significantly to adverse events in the context of heart failure. Congestion is difficult to detect and diuretics – the cornerstone of congestion management – have no high-quality efficacy and safety evidence. Even more, observational data indicates potential harm of diuretic treatment. The present research analyses the complex relationship between congestion, its treatment and heart failure outcome. The results indicate that persistent congestion is deleterious, and treatment with intensive diuretic regimen might be beneficial. Novel tools of congestion detection and grading were identified. All of them have the potential to be translated from the research field to daily clinical practice, after their impact on hard outcome is investigated in appropriate interventional trials.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results